

AC IMMUNE ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING

Lausanne, Switzerland, June 28, 2017 – AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the shareholders of the Company have approved all resolutions as proposed by the Board of Directors at the Company's Annual General Meeting which took place today in Lausanne, including:

- The annual report and the financial statements for the year 2016
- The appropriation of loss
- The discharge of the members of the Board of Directors and the Executive Committee
- The compensation for the members of the Board of Directors and the Executive Committee
- The re-election of the Members of the Board and the Members of the Compensation, Nomination and Corporate Governance Committee
- The re-election of the independent proxy and auditors of the company

Martin Velasco, Chairman of the Board of Directors, commented, "I would like to thank our shareholders for their continued trust and support. We are executing a clear strategy to create long-term value and mitigate risk, and over the past year have significantly strengthened our team of world-class life science professionals. A strong focus is our growing investment in and leveraging of our unique platforms to accelerate the development of neuro-orphan therapies and the discovery of neuroinflammation drug candidates."

More information on the Annual General Meeting is available on the [Company's website under the section investor](#).

About AC Immune

AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer's disease. The Company's pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Aβ antibody in phase 3 clinical studies that is being advanced by the collaboration partner Genentech, Inc., a wholly owned subsidiary of Roche. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.

Forward looking statements

This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information—Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

For further information please contact:

<p>Prof. Andrea Pfeifer Chief Executive Officer Phone: +41-21-345 91 21 E-mail: andrea.pfeifer@acimmune.com</p>	<p>Eva Schier Corporate Communications Manager Phone: +41-21-345 91 34 Mobile: +41 79 926 66 03 E-mail: eva.schier@acimmune.com</p>
<p>Nick Miles/ Toomas Kull Cabinet Privé de Conseils s.a. Phone : +41 22 552 46 46 E-mail : miles@cpc-pr.com kull@cpc-pr.com</p>	<p>In the US Ted Agne The Communications Strategy Group Inc. Phone: +1 781 631 3117 E-mail: edagne@comstratgroup.com</p>